Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

519 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Risk factors for prostate cancer.
Pienta KJ, Esper PS. Pienta KJ, et al. Ann Intern Med. 1993 May 15;118(10):793-803. doi: 10.7326/0003-4819-118-10-199305150-00007. Ann Intern Med. 1993. PMID: 8470854 Review.
Effects of extracellular matrix components and dihydrotestosterone on the structure and function of human prostate cancer cells.
Murphy BC, Pienta KJ, Coffey DS. Murphy BC, et al. Among authors: pienta kj. Prostate. 1992;20(1):29-41. doi: 10.1002/pros.2990200105. Prostate. 1992. PMID: 1371008
Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility.
Pienta KJ, Murphy BC, Isaacs WB, Isaacs JT, Coffey DS. Pienta KJ, et al. Prostate. 1992;20(3):233-41. doi: 10.1002/pros.2990200308. Prostate. 1992. PMID: 1374181
4-Hydroxyphenylretinamide in the chemoprevention of cancer.
Naik HR, Kalemkerian G, Pienta KJ. Naik HR, et al. Among authors: pienta kj. Adv Pharmacol. 1995;33:315-47. doi: 10.1016/s1054-3589(08)60673-0. Adv Pharmacol. 1995. PMID: 7495674 Review.
The effect of maltose tetrapalmitate (MTP) on prostate cancer growth in vivo and in vitro.
Nguyen NM, Lehr JE, Shelley CI, Andersen JC, Pienta KJ. Nguyen NM, et al. Among authors: pienta kj. Anticancer Res. 1993 Nov-Dec;13(6A):2053-8. Anticancer Res. 1993. PMID: 7507653
Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo.
Nguyen NM, Lehr JE, Pienta KJ. Nguyen NM, et al. Among authors: pienta kj. Anticancer Res. 1993 Nov-Dec;13(6A):2143-7. Anticancer Res. 1993. PMID: 7507655
Tumor-associated angiogenesis in prostate cancer.
Fregene TA, Khanuja PS, Noto AC, Gehani SK, Van Egmont EM, Luz DA, Pienta KJ. Fregene TA, et al. Among authors: pienta kj. Anticancer Res. 1993 Nov-Dec;13(6B):2377-81. Anticancer Res. 1993. PMID: 7510938
Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer.
Montie JE, Pienta KJ. Montie JE, et al. Among authors: pienta kj. Urology. 1994 Jun;43(6):892-9. doi: 10.1016/0090-4295(94)90163-5. Urology. 1994. PMID: 7515207 Review.
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE. Pienta KJ, et al. J Clin Oncol. 1994 Oct;12(10):2005-12. doi: 10.1200/JCO.1994.12.10.2005. J Clin Oncol. 1994. PMID: 7523606 Clinical Trial.
Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells.
Silletti S, Yao JP, Pienta KJ, Raz A. Silletti S, et al. Among authors: pienta kj. Int J Cancer. 1995 Sep 27;63(1):100-5. doi: 10.1002/ijc.2910630118. Int J Cancer. 1995. PMID: 7558435
519 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback